Clearmind Medicine INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Iroquois Capital Management, LLC, along with Richard Abbe and Kimberly Page, has disclosed a significant beneficial ownership stake in Clearmind Medicine Inc. through the exercise of warrants, subject to ownership limitations.
NASDAQ
L.I.A. Pure Capital Ltd. has filed an amendment to its Schedule 13G, reporting a 0% beneficial ownership stake in Clearmind Medicine Inc.
NASDAQ
L.I.A. Pure Capital Ltd. has reported a 5.0% beneficial ownership stake in Clearmind Medicine Inc., primarily through common shares, a convertible note, and a pre-funded warrant.
NASDAQ
Capitalink Ltd. has reported a 5.0% beneficial ownership stake in Clearmind Medicine Inc., including shares from a convertible note and warrant.
NASDAQ
Iroquois Capital Management, Richard Abbe, and Kimberly Page disclose beneficial ownership of up to 9.99% of Clearmind Medicine Inc. common stock.
NASDAQ
SCHEDULE 13G/A: Capitalink Ltd. Discloses 9.97% Stake in Clearmind Medicine
Capitalink Ltd. has filed an amended Schedule 13G, reporting a 9.97% beneficial ownership stake in Clearmind Medicine Inc., holding 5,980,397 common shares.
NASDAQ
SCHEDULE 13G/A: L.I.A. Pure Capital Discloses 9.97% Stake in Clearmind Medicine
L.I.A. Pure Capital Ltd. reported a 9.97% beneficial ownership stake in Clearmind Medicine Inc. as of December 3, 2025.
NASDAQ
L.I.A. Pure Capital Ltd. has reported a beneficial ownership of 9.99% in Clearmind Medicine Inc., holding 3,307,291 common shares.
NASDAQ
Capitalink Ltd. has reported a 9.99% beneficial ownership stake in Clearmind Medicine Inc., as detailed in a recent Schedule 13G filing.
NASDAQ
Nissim Daniel has reported beneficial ownership of 9.99% of Clearmind Medicine Inc.'s common shares, totaling 3,307,291 shares.
NASDAQ
Iroquois Capital Management, LLC and its principals, Richard Abbe and Kimberly Page, reported significant beneficial ownership in Clearmind Medicine Inc., primarily through warrants.
NASDAQ
AdvisorShares Trust has filed an amended Schedule 13G, reporting a 4.83% passive beneficial ownership stake in Clearmind Medicine Inc., holding 205,933 common shares.
NASDAQ
SCHEDULE 13G/A: Iroquois Capital Management and Affiliates Disclose Amended Beneficial Ownership in Clearmind Medicine Inc.
Iroquois Capital Management, LLC, Richard Abbe, and Kimberly Page have filed an amended Schedule 13G, disclosing their beneficial ownership of Clearmind Medicine Inc. common stock and warrants as of December 31, 2024.